Harnessing deep learning
to prevent blindness

Learn how Eyenuk can help

Eyenuk Launches EyeArt AI System in South Africa in Collaboration with Discovery Health

December 7, 2021

A new diabetic retinopathy screening benefit enabled by the EyeArt® AI system is made available by Discovery Health, a global leader in Healthcare and Financial Services Los Angeles, December 7, 2021 — Eyenuk, Inc., a…

Read More »

Eyenuk Announces Publication of Strong EyeArt® Pivotal Clinical Trial Results in JAMA Network Open

November 15, 2021

The published results demonstrate exceptional EyeArt accuracy in a pre-registered, prospective, multicenter clinical trial Los Angeles, November 15, 2021 — Eyenuk, Inc., a global artificial intelligence (AI) medical technology and services company and the leader…

Read More »

Eyenuk Applauds CMS CY 2022 Medicare Physician Fee Schedule Final Rule to Establish National Price for Autonomous AI Technology

November 4, 2021

 The CMS Final Rule establishes a national payment for CPT code 92229 that describes Eyenuk’s FDA-cleared EyeArt® AI system and confirms that AI can be used to close care gaps under the Merit-based Incentive Payment…

Read More »

Visit Eyenuk at the American Society of Retina Specialists 39th Annual Scientific Meeting

October 9, 2021

October 9, 2021 – Eyenuk is proud to sponsor the American Society of Retina Specialists (ASRS) 39th Annual Scientific Meeting this year in San Antonio, TX. Visit Eyenuk at booth #818 in the exhibit hall…

Read More »

Visit Eyenuk at The Retina Society’s 54th Annual Scientific Meeting

September 30, 2021

September 30, 2021 – Eyenuk is a proud sponsor of The Retina Society’s 54th Annual Scientific Meeting, being held at the Ritz-Carlton Chicago (Chicago, IL). Come visit us to learn more about our EyeArt® AI…

Read More »

Introducing EyeArt®

EyeArt is the first FDA cleared AI technology for autonomous detection of both more than mild and vision-threatening diabetic retinopathy. The EyeArt® AI Eye Screening System is the most extensively validated autonomous AI technology, tested on over half a million patient visits globally with over two million images collected in real-world clinical environments.

     Watch Video     
   Product Tour      
Real World Use

* EyeArt® has US FDA clearance, CE marking as a class IIa medical device in the European Union, and a Health Canada license.

EyeArtImages_for_US-FDA-resized

How can EyeArt Help?

The EyeArt system provides automated diabetic retinopathy screening without the need for expert human grading or eye dilation, enabling imaging, grading and reporting in a single office visit.

What does EyeArt Do?

The EyeArt system autonomously analyzes patient's retinal images acquired using an integrated fundus camera, robustly detects signs of disease, and returns an easy-to-read report in under 60 seconds.

How does EyeArt Work?

The EyeArt system incorporates a number of deep learning and image analysis algorithms to automatically assess the quality of the images, detect the presence and extent of lesions, and determine level of disease based on internationally recognized clinical scales.

 

Why choose EyeArt?

The EyeArt system is the world’s most-validated artificial intelligence (AI) screening tool for diabetic retinopathy, demonstrating high real-world sensitivity and specificity. It is proven to be safe, fast, and consistent.

Exceptional Performance in Pivotal, Prospective, Multi-Center Clinical Trial

EyeArt System Achieved 95.5% Sensitivity, 86.5% Specificity and 97% Imageability, While Meeting All Primary Endpoints with p<0.0001

Dr. Jennifer I. Lim, MD, Marion H. Schenk Esq. Chair, Professor of Ophthalmology, and Director of Retina Service at the University of Illinois at Chicago presented the Eyenuk Clinical Trial study results at the ARVO 2019 Imaging in the Eye Conference in Vancouver, Canada. Dr. Lim spoke to MD Magazine about the study in a multi part interview series. Click on the video to watch the interview.

Safe and effective in the real world

In a study with over 100,000 consecutive patient visits, EyeArt reports a 91.3% sensitivity and 91.1% specificity for referable DR and a 98.5% sensitivity for vision-threatening DR.

Experience EyeArt

Elevate Patient Care with the Confidence of AI Eye Screening

The high-performance EyeArt AI algorithm automatically detects diabetic retinopathy quickly, accurately, and consistently, with higher sensitivity than an eye care expert trained in image grading.

The EyeArt system is easy to use and with minimal training can be employed by nurses or technicians, enabling diabetic retinopathy screening at the point of care and eliminating an eye care specialist appointment just for screening.

Know More ▶

Elevate Patient v1

Undiagnosed Diabetic Retinopathy is a Thing of the Past

AI Eye Screening with EyeArt helps remove the biggest obstacle to annual DR screening and diagnosis: patient compliance.

The EyeArt system makes it possible for any physician to identify patients with vision-threatening retinopathy in-clinic, in real-time, so they can be immediately referred to an eyecare specialist for treatment to save their sight.

Know More ▶

Test and Give Results to Patients in the Same Appointment

Whether you work with diabetes patients as a general practitioner, endocrinologist, diabetologist, ophthalmologist, or an optometrist, EyeArt can enable fast, reliable, and accurate diabetic retinopathy screening for your patients.

Find out how easy it is to incorporate the EyeArt system into your practice.

Know More ▶

Want to try EyeArt?

EyeArt can be seamlessly integrated with your clinical workflow to enable automated DR screening.
Click to get started.

Experience EyeArt

* EyeArt® has US FDA clearance, CE marking as a class IIa medical device in the European Union, and a Health Canada license.

Our Product Suite

Products under development. Click here to know more. 

EyeMark™

Accurately Track
Retinopathy Progression

EyeSee™ AMD

Fully-Automated
AMD screening

EyeSee™ Glaucoma

Fully-Automated Glaucoma screening

EyeRead™ UWF

Lesion Analysis in
UWF images

* EyeMark™, EyeRead™UWF, EyeSee™AMD, EyeSee™Glaucoma have not yet been cleared for sales in any region.

advisor-1

EyeArt could have a huge impact in improving the lives of individuals with diabetes who still face the risk of losing vision asymptomatically

Prof. Andrew Boulton, MD, DSc(Hon), FACP, FRCP

Renowned Diabetes Expert, Professor of Medicine, University of Manchester, UK
collaborators-2

I believe that an automated, reliable DR screening tool such as EyeArt would empower primary care providers to better manage their patients with diabetes.

Srinivas Sadda, MD

President and CSO, Doheny Eye Institute, Los Angeles, USA
collaborators-3

I believe that automation of common tasks like DR screening would have a tremendous impact on the quality and extent of vision care for the disparity populations. Therefore I am eager to work with EyeArt tool for DR screening.

Dr. Todd Margolis, MD, PhD

Distinguished Professor and Chairman, Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, MO, USA (Former President of ARVO)
collaborators-1

...results of the large scale validation on over 100,000 patient encounters from the EyePACS database are highly encouraging and show that EyeArt can be a safe and effective alternative to manual screening.

Dr. Jorge Cuadros, OD, PhD

CEO of EyePACS, Assistant Clinical Professor, UC Berkeley School of Optometry, CA, USA
DrLaurenDaskivich

EyeArt’s automatic lesion detection and DR screening will allow us to better monitor our teleretinal patients at a lower cost in the under-resourced setting in which we care for Los Angeles’s most disadvantaged patients.

Dr. Lauren P. Daskivich, MD, MSHS

Director of Ophth. and Eye Health Programs, LA County Department of Health Services, Los Angeles, CA, USA

Eyenuk in the news

Select Collaborators, Customers, & Partners

The Doheny Eye Institute in Los Angeles, CA is recognized as a leading center for eye disease and vision research.

The Los Angeles County Department of Health Services safety net serves more than 800K patients annually and runs a teleretinal DR screening program.

Madras Diabetes Research Foundation (MDRF) in India was established in 1996. It's a premier research institute for diabetes and its complications.

Washington University School of Medicine, St. Louis, MO is one of the leading medical research, teaching and patient care institutions in the US.

The Armenian Eyecare Project (AECP) is a nonprofit organization dedicated to providing the Armenian people eye care to help eliminate preventable blindness.

Diabetes Clinic Bad Mergentheim (Germany) is a specialist hospital for inpatient diabetes treatment.

The National Health Service (NHS) is the public health service system of the United Kingdom. NHS runs the largest DR screening program in the world.

CAMO, the Ambrosian Ophthalmic Center, is an eye clinic of excellence, in Milan, for diagnostics, correction of visual defects and treatment of eye diseases.

Eye Picture Archive Communication System is a non-proprietary web-based application for exchanging eye-related clinical information  .